Outsource Research
There are many good reasons for your organisation to completely or partially outsource research on a contract basis, i.e., contract research. Collaborating with the Amsterdam research landscape not only saves time and reduces costs, your company will also benefit enormously by gaining access to specialised knowledge or expertise, and cutting-edge facilities. For instance:
- laboratory experiments
- production of (small quantities) of specific compounds or materials (contract manufacturing)
- access to high-tech facilities such as lab facilities, advanced equipment, databases or rare collections and archives
- further development and/or validation of methodologies
Continue reading after the photo.
Good agreements and legal contracts
Successful collaborations start with good agreements. In contract research and contract manufacturing, you determine together with the researcher what is to be expected in terms of output (data, materials, inventories, reports etc.) and standards (quality standards etc.). Besides discussing which joint efforts are needed to deliver the required outcomes, financial and legal matters have to be tackled, such as fees, intellectual property rights and ownership on application.
IXA’s legal experts and business developers provide support and advice in the negotiations and in drafting public-private partnership contracts. These contracts will be fine-tuned to the particular nature of the activities and the needs and interests of the parties involved.
Innovation Awards 2021 uitgereikt
Amsterdamse Science & Innovation Awards 2021 voor digitale urineweegschaal, nanofolie en dyslexiespel voor kinderen In NEMO Amsterdam zijn voor de 15e keer de jaarlijkse Innovation Awards uitgereikt. De innovatieprijzen zijn een initiatief van Innovation Exchange Amsterdam (IXA). IXA bekroont met de Awards vernieuwende ideeën van jonge onderzoekers, verbonden aan de Amsterdamse universiteiten en kennisinstellingen. Tom […]
News
Amsterdam UMC proudly presents new spin-off Kling BioTherapeutics
Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a novel discovery platform and a robust pipeline of first in […]
News
Bestaand medicijn verbetert prikkelverwerking bij kinderen met autisme
Een veilig medicijn tegen hoge bloeddruk helpt kinderen met autisme prikkels beter te verwerken; een studie van Amsterdam UMC bewijst dit. Daarnaast ontwikkelden de onderzoekers een algoritme dat helpt voorspellen bij welke kinderen dit middel werkt. “Deze methode brengt een eerste behandeling op maat in de kinder- en jeugdpsychiatrie”, aldus hoofdonderzoeker Hilgo Bruining. Uit het […]
News